Form 6-k

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of July 2011

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x            Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨                                   No x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-            

In July 2011, Sanofi issued the press releases attached hereto as Exhibits 99.1, 99.2 and 99.3 which are incorporated herein by reference.

Exhibit List

 

Exhibit No.

   

Description

Exhibit 99.1    Press release dated June 24, 2011: Sanofi Announces Positive Results from the “All to Target” Study Evaluating Two Lantus® and Apidra® Regimens versus Premixed Regimen
Exhibit 99.2    Press release dated June 24, 2011: Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association’s 71st Annual Scientific Sessions
Exhibit 99.3    Press release dated June 30, 2011: U.S. District Court Rules that Merial’s FRONTLINE Plus® Patent is valid

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: July 6, 2011      

     SANOFI

   

By    

  

                /S/     John Felitti        

      Name:    John Felitti
      Title:     Associate Vice President,
     

              Corporate Law, Financial &

              Securities Law

 

3

Exhibit Index

 

Exhibit No.

   

Description

Exhibit 99.1    Press release dated June 24, 2011: Sanofi Announces Positive Results from the “All to Target” Study Evaluating Two Lantus® and Apidra® Regimens versus Premixed Regimen
Exhibit 99.2    Press release dated June 24, 2011: Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association’s 71st Annual Scientific Sessions
Exhibit 99.3    Press release dated June 30, 2011: U.S. District Court Rules that Merial’s FRONTLINE Plus® Patent is valid

 

4